Table 1.

Findings of the NMA of cumulative clinical benefits

Treatment	Mean difference (95% CrI) in number of days with PASI 100 for BKZ 320 mg Q4W/Q8W versus comparatorsa
Bimekizumab 320 mg Q4W/Q8Wb	Reference
Bimekizumab 320 mg Q4W/Q4W	− 0.10 (− 16.88, 16.50)
Brodalumab 210 mg	− 38.68 (− 63.38, − 14.10)
Risankizumab 150 mg	− 15.31 (− 38.29, 7.39)
Ixekizumab 80 mg	− 37.74 (− 70.43, − 5.88)
Guselkumab 100 mg	− 38.78 (− 61.93, − 15.95)
Secukinumab 300 mg	− 53.81 (− 71.33, − 36.61)
Ustekinumab 45 or 90 mg	− 102.14 (− 121.05, − 83.46)
Secukinumab 150 mg	− 102.90 (− 123.78, − 82.34)
Adalimumab 40 mg	− 100.68 (− 129.30, − 72.31)
Etanercept 50 mg	− 138.80 (− 160.85, − 116.84)

BKZ bimekizumab, CrI credible interval, NMA network meta-analysis, PASI 100 achievement of 100% improvement from baseline in Psoriasis Area and Severity Index, Q4W every 4 weeks, Q8W every 8 weeks

^aNMA of cumulative clinical benefits from weeks 0–52. Model: fixed effects NMA

^bBimekizumab-treated patients were dosed 320 mg every 4 weeks through week 16 and then switched to every 8 weeks maintenance dosing (Q4W/Q8W)